Abstract
Numerous types of nanoparticles are being designed for systemic and targeted drug delivery. However, keeping nanoparticles in blood for sufficiently long times so as to allow them to reach their therapeutic target is a major challenge. Upon administration into blood, nanoparticles are quickly opsonized and cleared by the macrophages, thereby limiting their circulation times. Surface-modification of nanoparticles by PEG was developed as the first strategy to prolong nanoparticle circulation. While PEGylation has helped prolong particle circulation, it has several limitations including transient nature of the effect and compromised particle-target interactions. Accordingly, several other approaches have been developed to prolong nanoparticle circulation in blood. These include modification with CD47, modulation of mechanical properties, engineering particle morphology and hitchhiking on red blood cells. In this review, we discuss the factors that affect nanoparticle circulation time and discuss recent progress in development of strategies to prolong circulation time.
Keywords: Nanotechnology, targeting, long-circulation, macrophage, half-life, nanomedicine
Current Pharmaceutical Design
Title: Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Volume: 16 Issue: 21
Author(s): Jin-Wook Yoo, Elizabeth Chambers and Samir Mitragotri
Affiliation:
Keywords: Nanotechnology, targeting, long-circulation, macrophage, half-life, nanomedicine
Abstract: Numerous types of nanoparticles are being designed for systemic and targeted drug delivery. However, keeping nanoparticles in blood for sufficiently long times so as to allow them to reach their therapeutic target is a major challenge. Upon administration into blood, nanoparticles are quickly opsonized and cleared by the macrophages, thereby limiting their circulation times. Surface-modification of nanoparticles by PEG was developed as the first strategy to prolong nanoparticle circulation. While PEGylation has helped prolong particle circulation, it has several limitations including transient nature of the effect and compromised particle-target interactions. Accordingly, several other approaches have been developed to prolong nanoparticle circulation in blood. These include modification with CD47, modulation of mechanical properties, engineering particle morphology and hitchhiking on red blood cells. In this review, we discuss the factors that affect nanoparticle circulation time and discuss recent progress in development of strategies to prolong circulation time.
Export Options
About this article
Cite this article as:
Yoo Jin-Wook, Chambers Elizabeth and Mitragotri Samir, Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects, Current Pharmaceutical Design 2010; 16 (21) . https://dx.doi.org/10.2174/138161210791920496
DOI https://dx.doi.org/10.2174/138161210791920496 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives of Fullerenes, Dendrimers, and Heterocyclic Compounds Application in Tumor Treatment
Recent Patents on Nanomedicine Patent Selections
Recent Patents on Biotechnology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry The Yin and Yang of microRNA Assay Methods
MicroRNA Editorial (Thematic Issue: Special Issue on Herbal Medicines and Nano-Drug Delivery Systems)
Current Signal Transduction Therapy Cell-Based Assay System to Estimate the Effect of 125I Seeds on Cancer Cells: Effect of Osteopontin
Recent Patents on Anti-Cancer Drug Discovery Cyclooxygenase-2 (COX-2) Mediates Arsenite Inhibition of UVB-Induced Cellular Apoptosis in Mouse Epidermal Cl41 Cells
Current Cancer Drug Targets Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Molecular Response to Hypericin-Induced Photodamage
Current Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry